Skip to main content

Recent Publications

Browse recent studies from the Lou and Jean Malnati Brain Tumor Institute to learn more about our cutting-edge research.

  1. Luo M, Wu S, Huang C, Zheng Z, Xia Q, Li Y, Zhou X, Hong S, Zhong R, Li W  et al.  Inhibition of PRMT5-Dependent YAP Methylation Attenuates Tumorigenicity and Radioresistance in Glioblastoma.  Cancer Lett  2026 Feb 07;:218308. doi:10.1016/j.canlet.2026.218308
  2. Li X, Han Z, Sun S, Wu Y, Zhang X, Yin Y, Zhao Z, Hai J, Wang B  Chiral Cascade-Targeted Nanoassembly Eradicates Intratumoral Bacteria via Ferroptosis to Potentiate STING-Driven Antitumor Immunity.  ACS Appl Mater Interfaces  2026 Feb 04;18(4):6610-6625. doi:10.1021/acsami.5c24093
  3. Lukas RV, Du R, Congivaram H, McCortney K, Dixit K, Horbinski C, Schwartz M, Lezon R, Singer L, Primdahl D  et al.  Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.  JCI Insight  2026 Feb 03;. pii:e198475
  4. Lalchungnunga H, Dampier CH, Singh O, Hoang DT, Shulman ED, Abdullaev Z, Li B, Luo Z, Wu Z, Pearce TM  et al.  Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study.  Lancet Oncol  2026 Feb;27(2):243-253. doi:10.1016/S1470-2045(25)00661-8
  5. Budhiraja S, Faisal UH, Baisiwala S, Chojak R, Koutah L, Drewes NB, Cho S, Kazi HA, Chen R, Perrault EN  et al.  THOC1 complexes with SIN3A to regulate R-loops and promote glioblastoma progression.  Neoplasia  2026 Feb;72:101271. pii:101271
  6. Mehta MP, Gondi V, Ahluwalia MS, Roberge D, Sio TTW, Trifiletti DM, Muanza T, Krpan AM, Zhu Z, Ramakrishna NR  et al.  Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study.  Int J Radiat Oncol Biol Phys  2026 Feb 01;124(2):278-293. doi:10.1016/j.ijrobp.2025.08.066
  7. Dixit KS, Kumthekar P, Lukas RV, Williams A, Tate MC, Chandler JP, Jamshidi P, Helenowski I, Zhang H, Bloch O  et al.  A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.  J Neurooncol  2026 Jan 28;176(3):185. doi:10.1007/s11060-026-05446-1
  8. LaBella D, Schumacher K, Mix M, Leu K, McBurney-Lin S, Nedelec P, Villanueva-Meyer J, Raleigh DR, Shapey J, Vercauteren T  et al.  The 2024 Brain Tumor Segmentation Challenge Meningioma Radiotherapy (BraTS-MEN-RT) dataset.  Sci Data  2026 Jan 27;. doi:10.1038/s41597-026-06649-x
  9. Zhu L, Kinjawadekar I, Prempeh C, Nikonorova IA, Mirek ET, Lopez EM, Jonsson WO, Levy JL, Wang L, Li X  et al.  A metabolic basis for motor deficits in mice lacking BCKDK.  J Nutr Biochem  2026 Jan 24;:110275. doi:10.1016/j.jnutbio.2026.110275
  10. Asogwa OA, Dirven L, Aaronson NK, Baumert BG, van den Bent M, Brandes AA, Clement PM, Coens C, Chinot O, Gorlia T  et al.  Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis.  Oncologist  2026 Jan 22;. pii:oyag005
  11. Lassman AB, Polley MC, Iwamoto FM, Gondi V, Sulman EP, Wolchok JD, Mehta MP  Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.  J Clin Oncol  2026 Jan 16;:JCO2502821. doi:10.1200/JCO-25-02821
  12. Jones G, Murphy A, Lee-Chang C  B cell immunity and therapeutic opportunities in brain metastases.  Front Immunol  2025;16:1740386. pii:1740386
  13. Khan F, Petrosyan E, Liu Y, Bahrami A, Taefi E, Geula C, Lesniak MS, Chen P  Microglial TBK1 Signaling Promotes Breast Cancer Brain Metastasis.  Cancer Res  2026 Jan 02;86(1):12-21. doi:10.1158/0008-5472.CAN-25-1791
  14. Pendyala P, Ufondu A, Gondi V  Innovations in Whole Brain Radiation Therapy.  Cancer J  ;32(1). pii:e0810
  15. Trautmann RK, Dennison N, McCortney K, Klier S, Cosacak MI, Werner C, Akyoldas G, Horbinski CM, Freudenberg U, Kizil C  High-Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening.  Macromol Biosci  2026 Jan;26(1):e00394. pii:e00394
  16. Wu M, Yang Y, Zhang J, Efimov AI, Li X, Zhang K, Wang Y, Bodkin KL, Riahi M, Gu J  et al.  Patterned wireless transcranial optogenetics generates artificial perception.  Nat Neurosci  2026 Jan;29(1):234-245. doi:10.1038/s41593-025-02127-6
  17. Li J, Ross JL, Hambardzumyan D, Brat DJ  Immunopathology of Glioblastoma.  Annu Rev Pathol  2026 Jan;21(1):135-162. doi:10.1146/annurev-pathmechdis-042524-025950
  18. He Z, Li W, Liu T, Li X, Han J, Zhang T, Yuan Y  GAGM: Geometry-aware graph matching framework for weakly supervised gyral hinge correspondence.  Med Image Anal  2026 Jan;107(Pt A):103820. doi:10.1016/j.media.2025.103820
  19. Aggarwal A, Youngblood MW, Picart T, Najem H, Oten S, Cady MA, Magill ST, Horbinkski CM, Chandler JP, Heimberger AB  et al.  Meningioma cell reprogramming and microenvironment interactions underlie brain invasion.  Neuro Oncol  2025 Dec 31;. pii:noaf292
  20. Duckett D, Santana-Santos L, McCord M, Smith V, Lopes MBS, Youngblood MW, Magill ST, Chandler JP, Heimberger AB, Lukas R  et al.  Development, validation, and utility of a clinically applicable methylation classifier for recurrence risk prediction in meningiomas.  Acta Neuropathol Commun  2025 Dec 29;13(1):259. pii:259
  21. Goerzen D, Kim M, Schroff C, Hoang MN, Wollowitz JS, Kolb A, Walshon JP, McCortney K, Horbinski C, Galbraith K  et al.  Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature.  Nat Nanotechnol  2025 Dec 24;. doi:10.1038/s41565-025-02080-2
  22. Olson IE, Chojak R, Faisal UH, Turunen J, Lazanyi I, Miska J, Ahmed AU  Use of Cerebral Open-Flow Microperfusion for the Longitudinal Collection of Interstitial Fluid in an Animal Model of Glioblastoma.  J Vis Exp  2025 Dec 23;(226). doi:10.3791/68748
  23. Amirkhani N, Maroufi F, Pour-Rashidi A, Shirani M, Chandler JP  Impact of anti-seizure medication duration on postoperative seizures following supratentorial high-grade glioma resection: a mixed-model and tree-based approach.  J Neurooncol  2025 Dec 23;176(2):134. doi:10.1007/s11060-025-05373-7
  24. Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E  et al.  Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models.  PLoS One  2025;20(12):e0323235. pii:e0323235
  25. Visa MA, Liggett MR, Lashley S, Bhatti U, Dawood ZA, Anand A, Gill NP, Scholtens DM, Wang B, Alam HB  Valproic acid for treatment of traumatic brain injury: Study protocol for the VIBRANT prospective randomized trial.  Transfusion  2025 Dec 20;. doi:10.1111/trf.70029
  26. Aucoin L, Templer JW, Tate MC, Dixit KS  The role of a multidisciplinary clinic for management of patients with IDH mutant gliomas.  Front Oncol  2025;15:1729589. pii:1729589
  27. Youngblood MW, Kumari A, Kang YT, Gould A, Habashy K, Gomez M, Lingamarla H, Morey T, Chen L, Congivaram H  et al.  Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.  Nat Commun  2025 Dec 16;16(1):11045. pii:11045
  28. Li Y, Sheng M, Li W, Liu S, Wang B, Liu B, Luo M, Zhou X, Xia Q, Hong S  et al.  Targeting chaperone-mediated autophagy inhibits properties of glioblastoma stem cells and restores anti-tumor immunity.  Nat Commun  2025 Dec 13;17(1):440. pii:440
  29. Song X, Tiek D, Lu M, Yu X, Wu R, Walker M, He Q, Sisbarro D, Hu B, Cheng SY  A single-cell atlas of RNA alternative splicing in the glioma-immune ecosystem.  Genome Biol  2025 Dec 12;26(1):426. pii:426
  30. Colman H, Lombardi G, Wong ET, Walbert T, Eoli M, Lassman AB, Peereboom DM, Kizilbash SH, Kamiya-Matsuoka C, Pitz MW  et al.  STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.  J Clin Oncol  2025 Dec 01;:JCO2501204. doi:10.1200/JCO-25-01204
  31. Nguyen TH, Nguyen HT, Vu V, Lam BT, Huynh P, Wang T, Li X, Bagci U, Xu M  DuetMatch: Harmonizing semi-supervised brain MRI segmentation via decoupled branch optimization.  Comput Med Imaging Graph  2025 Dec;126:102666. doi:10.1016/j.compmedimag.2025.102666
  32. Sadagopan NS, Gomez M, Tripathi S, Billingham LK, DeLay SL, Cady MA, Congivaram HTS, Chia TY, Wan H, Wang S  et al.  NOTCH3 drives fatty acid oxidation and ferroptosis resistance in aggressive meningiomas.  J Neurooncol  2025 Dec;175(3):979-991. doi:10.1007/s11060-025-05208-5
  33. Fanuzzi M, Zheng S, Horbinski CM, Shaaban MA, Congivaram H, Du R, Tripathi S, Hurley L, Kumthekar P, Ahmed A  et al.  Targeting Survivin: Now I Become Death, the Destroyer of Cells.  Int J Mol Sci  2025 Nov 26;26(23). pii:11417
  34. Sears TK, McCord M, Wang W, Steffens A, McCortney K, Chaliparambil R, Sarkaria JN, Horbinski CM  Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas.  JCI Insight  2025 Nov 24;10(22). pii:e195385
  35. Saathoff MR, Chojak R, Chen RX, Kazi HA, Faisal UH, Shireman JM, Drewes N, Park CH, Fan X, Khan SA  et al.  LMNA-PRKDC axis enhances DNA repair and promotes chemoresistance in glioblastoma.  Cell Death Dis  2025 Nov 21;17(1):50. pii:50
  36. Stitzlein LM, Nam D, Hernandez FA, Patel KH, Poche A, Ma H, Impelman K, Gumin J, Wang H, Wang J  et al.  Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma.  Neurooncol Adv  2025;7(1):vdaf246. pii:vdaf246
  37. Jin Z, Li X, Hou X, Hu J, Zhuo Y, Shi J, Xu T, Zhao Q, Jing Z  Single-atom Ca nanozyme induces glioma death through Ca2+-overload-enhanced catalytic tumor nanotherapy, ferroptosis and synergistic remodeling of the immune microenvironment.  J Nanobiotechnology  2025 Nov 13;23(1):716. pii:716
  38. Mahajan AS, Dussold C, Kim S, Jarvis R, Hurley LA, Tommasini-Ghelfi S, Park J, Forsyth CM, Zhang B, Miska J  et al.  cGAS-agonistic spherical nucleic acids reprogram the glioblastoma immune microenvironment and promote antitumor immunity.  Proc Natl Acad Sci U S A  2025 Nov 11;122(45):e2409557122. pii:e2409557122
  39. Tiek D, Song X, Wu R, Yu X, Walker M, Mao Y, Sisbarro D, He Q, Magassa A, Singh A  et al.  Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds.  Neuro Oncol  2025 Nov 10;. pii:noaf265
  40. Gondi V, Pugh SL, Mehta MP, Wefel JS, Tomé WA, Sun AY, Grecula J, Redmond KJ, Fogh S, Gaspar L  et al.  Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.  J Clin Oncol  2025 Nov 10;43(32):3516-3525. doi:10.1200/JCO-25-00221
  41. De La Fuente MI, Brastianos PK, Gampel B, Nassiri F, Raleigh DR, Ida CM, Abdelbaki MS, Pekmezci M, Bagley S, Young JS  et al.  Reflecting on Scientific Growth and Innovation as the Society for Neuro-Oncology Turns 30.  Neuro Oncol  2025 Nov 04;. pii:noaf255
  42. Le Rhun E, Sain D, Erridge SC, Reardon DA, Minniti G, Roth P, Wick W, Nabors B, Sampson J, Mason W  et al.  Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma.  JAMA Netw Open  2025 Nov 03;8(11):e2545578. pii:e2545578
  43. Khalili BF, Chojnacki MR, Dixit K, Gururangan K, Horbinski C, Rosenow JM, Hsieh JK, Magill ST, Tate MC, Lukas RV  et al.  Surgical Treatment of Brain Tumor-Related Epilepsy: Current and Emerging Strategies.  Cancers (Basel)  2025 Nov 01;17(21). pii:3539
  44. Hu W, Zhao C, Zheng W, Lin Y, Luo N, Liu H, Wang X, Qi X, Wang X, Li XN  et al.  Use of integrated spatial transcriptomics and histopathological analysis in adamantinomatous craniopharyngiomas to identify stromal cells as a new cellular source of leukemia inhibitory factor.  J Neurosurg  2025 Nov 01;143(5):1336-1349. doi:10.3171/2025.4.JNS243146
  45. Myneni S, Tang L, Akbari H, Mayne R, Kazemi F, Xiong R, Redmond KJ, Bilsky MH, Charest-Morin R, Tobert DG  et al.  The Spinal Chordoma Patient Reported Outcome Survey (spCPROS): a patient-centered, disease-specific tool for assessing quality of life in spinal chordoma patients.  J Neurooncol  2025 Nov;175(2):813-824. doi:10.1007/s11060-025-05181-z
  46. Corn BW, Paulus R, Gondi V, Mehta MP, Fogh S, Wefel JS, Videtic GM, Sun A, Yoon H, Heinzerling JH  et al.  "Hope" Drives Quality of Life in Patients With Brain Metastases, But, the "Hope Center" Remains Elusive: An Analysis of NRG-CC003.  Int J Radiat Oncol Biol Phys  2025 Nov 01;123(3):642-652. doi:10.1016/j.ijrobp.2025.06.3884
  47. Gruchala T, Lewis CW, Abplanalp K, Jayabalan P, Walunas TL, Johnson JL, Wainwright DA, Lukas RV, Spill G, Roy I  Predicting medical prognosis in patients with glioblastoma during inpatient rehabilitation using bed mobility function.  PM R  2025 Nov;17(11):1343-1353. doi:10.1002/pmrj.13402
  48. Kamijo Y, Mächler P, Ness N, Vu CQ, Kusakizako T, Mannuthodikayil J, Ku Z, Boisvert M, Grebenik E, Miyazaki I  et al.  A red fluorescent genetically encoded biosensor for in vivo imaging of extracellular L-lactate dynamics.  Nat Commun  2025 Oct 29;16(1):9531. pii:9531
  49. Zannikou M, Duffy JT, Procissi D, Najem H, Levine RN, Thakur A, Hambardzumyan D, Lee-Chang C, Leoni L, Horbinski CM  et al.  Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models.  J Immunother Cancer  2025 Oct 28;13(10). pii:e011714
  50. Cherng HR, Sun K, Bentzen SM, Brown PD, Armstrong TS, Palmer JD, Gondi V, Mehta MP, Mishra MV  Redefining Neurocognitive Outcomes After Radiation for Brain Metastases: A Patient-Level Meta-Analysis of Recovery Following Initial Decline.  J Natl Cancer Inst  2025 Oct 22;. pii:djaf264
These are the publications from our team members that have been most recently indexed by PubMed. Visit PubMed to see more of our publications.

Follow MBTI on FacebookYouTubeLinkedInInstagram